TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How does linvoseltamab differ from other bispecific antibodies?

By Jennifer Reilly

Share:

Featured:

Naresh BummaNaresh Bumma

Sep 1, 2023

Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.


Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

Question 1 of 2

By September 2023, which bispecific antibodies have been approved by the FDA for the treatment of relapsed/refractory multiple myeloma?

A

B

C

D

The Multiple Myeloma Hub was pleased to speak to Naresh Bumma, The Ohio State University, Columbus, US. We asked, How does linvoseltamab differ from other bispecific antibodies?

How does linvoseltamab differ from other bispecific antibodies?

In this video interview, Naresh Bumma opens by discussing the latest approvals and developments in bispecific antibodies for the treatment of multiple myeloma. He goes on to present key efficacy and safety data from LINKER-MM1 trial (NCT03761108), highlighting the outcomes observed with linvoseltamab compared with data of alternative bispecific antibodies.
Bumma notes the similarity in response rates across the same drug class but highlights infection, neurotoxicity, ICANS and CRS rates as differentiators favoring linvoseltamab over existing bispecific antibodies.